Heather V Krell1, Andrew F Leuchter, Melinda Morgan, Ian A Cook, Michelle Abrams. 1. Laboratory of Behavioral Pharmacology, UCLA Neuropsychiatric Institute, and the Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024-1759, USA. hkrell@mednet.ucla.edu
Abstract
OBJECTIVE: To evaluate the association between treatment expectations and response in a 9-week, single-blind experimental antidepressant treatment study. METHOD: Twenty-five adult subjects meeting DSM-IV criteria for major depressive disorder with Hamilton Rating Scale for Depression (HAM-D) scores of >/= 17 completed a treatment trial using the experimental antidepressant reboxetine. Following a 1-week placebo lead-in, subjects received single-blind treatment for 8 weeks with reboxetine 8 to 10 mg/day. During the screening visit, subjects were asked to self-rate their expectations of the effectiveness of the study medication. Forced-choice responses were "not at all effective," "somewhat effective," or "very effective." Response to treatment was defined as a final HAM-D score of </= 10 at the end of the 9-week trial. Data were collected from October 1999 to July 2001. RESULTS: Subjects with a higher pretreatment expectation of medication effectiveness had a greater likelihood of response. Of the subjects who reported an expectation that the medication would be very effective, 90.0% (N = 9) responded to treatment, while only 33.3% (N = 5) of those who reported expecting medication to be somewhat effective responded to treatment (chi(2) = 7.819, p <.005). There was no association between the level of depression severity, duration of current episode, number of prior episodes, or basic demographic factors and treatment outcome. CONCLUSIONS: These findings indicate that individuals with high baseline expectations of improvement demonstrate a significantly higher level of response to reboxetine than those with lower expectations of improvement with treatment. The data in this study suggest that a subject's expectation of efficacy is associated with the outcome of experimental antidepressant treatment.
RCT Entities:
OBJECTIVE: To evaluate the association between treatment expectations and response in a 9-week, single-blind experimental antidepressant treatment study. METHOD: Twenty-five adult subjects meeting DSM-IV criteria for major depressive disorder with Hamilton Rating Scale for Depression (HAM-D) scores of >/= 17 completed a treatment trial using the experimental antidepressant reboxetine. Following a 1-week placebo lead-in, subjects received single-blind treatment for 8 weeks with reboxetine 8 to 10 mg/day. During the screening visit, subjects were asked to self-rate their expectations of the effectiveness of the study medication. Forced-choice responses were "not at all effective," "somewhat effective," or "very effective." Response to treatment was defined as a final HAM-D score of </= 10 at the end of the 9-week trial. Data were collected from October 1999 to July 2001. RESULTS: Subjects with a higher pretreatment expectation of medication effectiveness had a greater likelihood of response. Of the subjects who reported an expectation that the medication would be very effective, 90.0% (N = 9) responded to treatment, while only 33.3% (N = 5) of those who reported expecting medication to be somewhat effective responded to treatment (chi(2) = 7.819, p <.005). There was no association between the level of depression severity, duration of current episode, number of prior episodes, or basic demographic factors and treatment outcome. CONCLUSIONS: These findings indicate that individuals with high baseline expectations of improvement demonstrate a significantly higher level of response to reboxetine than those with lower expectations of improvement with treatment. The data in this study suggest that a subject's expectation of efficacy is associated with the outcome of experimental antidepressant treatment.
Authors: Bret R Rutherford; Joel R Sneed; Jane M Tandler; David Rindskopf; Bradley S Peterson; Steven P Roose Journal: J Am Acad Child Adolesc Psychiatry Date: 2011-06-15 Impact factor: 8.829
Authors: Suzanne M Bertisch; Anna R T Legedza; Russell S Phillips; Roger B Davis; William B Stason; Rose H Goldman; Ted J Kaptchuk Journal: J Eval Clin Pract Date: 2009-02 Impact factor: 2.431